Certolizumab Pegol in Crohn’s Disease
Certolizumab Pegol in Crohn’s Disease
European Gastroenterology & Hepatology Review Volume4 Issue 2
Published: October 2009
Published: October 2009
Crohn’s disease is a disorder characterised by chronic inflammation of the gastrointestinal mucosa. Individuals with Crohn’s disease can present with a variety of symptoms, including abdominal pain, diarrhoea, fistulae, vomiting or weight loss. Extraintestinal symptoms such as skin rashes and arthritis are not uncommon. Although the exact pathogenesis of Crohn’s disease is unknown, several lines of evidence suggest that it is a polygenic disease with compromised host defence as an important aetiological factor.1,2 Additional disease genes in the Th17 pathway may contribute to the heightened activation of immune and non-immune cells in the intestinal wall as well as systemically, which is typical for active Crohn’s disease. There is no known cure for Crohn’s disease, although current therapeutic regimens are able to confer some degree of relief and, for some patients, periods of remission.
Traditional Therapies in Crohn’s Disease
Anti-inflammatory drugs and oral immunosuppressants have traditionally been the mainstay for treating Crohn’s disease. While 5-aminosalicylic acid (ASA) compounds are standard therapy in ulcerative colitis, the other main inflammatory bowel disease, this approach appears to be less effective in Crohn’s disease; some formulations of mesalamine have given efficacy signals in mild to moderate Crohn’s disease,3–5 but large trials with mesalamine have failed to demonstrate superiority over placebo.6,7
To read full article please click here
Keywords:
Crohn’s Disease, Certolizumab Pegol, chronic inflammation, Anti-inflammatory drugs, oral immunosuppressants,
Crohn’s Disease, Certolizumab Pegol, chronic inflammation, Anti-inflammatory drugs, oral immunosuppressants,
